Compass Pathways PLC
Change company Symbol lookup
Select an option...
CMPS Compass Pathways PLC
BCLI Brainstorm Cell Therapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
SBFM Sunshine Biopharma Inc
SEKEY Seiko Epson Corp
PXMD PaxMedica Inc
CDT Conduit Pharmaceuticals Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc

Health Care : Biotechnology |
Based in United Kingdom
Company profile

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The Company is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
-0.07 (-0.89%)
B/A Size
Day's High
Day's Low

10-day average volume:

Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

10:28 am ET May 26, 2023 (MarketWatch)

By Barbara Kollmeyer

Ingredient found in magic mushrooms showed remission in patients after 18 months

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

Compass shares (CMPS) rose 3% after the London-based mental-health care group reported that more than half of patients treated with one 25 milligram dose of the COMP360 psilocybin treatment, alongside psychological support, showed remission of depression at 18 months.

COMP360 is a psychoactive substance found in hallucinogenic mushrooms. The study, led by Dr. Manich Agrawal at Sunstone Therapies, which carries out research on psychedelic therapies for cancer and other diseases and disorders, is believed to be the longest-ever conducted of a psilocybin therapy.

"The results show significant improvement in these patients' depression symptoms long-term and, if replicated in larger studies, could open the door to a wider and faster adoption of psilocybin therapy in the future," Agrawal said in a press release announcing the results.

The open-label follow-up study involved 30 patients with curable and incurable cancer and major depressive disorder. Of those, 64.2% showed "sustained clinical response" from baseline to 18 months follow-up, and 57.2% showed depression in remission at 18 months.

An original Phase 2 study of 30 patients, with a follow-up period of eight weeks, was completed in 2021 and published in April 2023, with 28 of those original patients enrolled in the study to track longer-term response.

Read:The promise and the perils of the billion-dollar industry blossoming around psychedelic-assisted therapy

The risk of depression in cancer patients is more than five times higher than within the general population, according to a study published in the European Journal of Cancer in 2017. Their study of more than 5,000 patients found that one in four were depressed.

Compass said the new long-term efficacy data of will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), expected to take place in early June.

Compass stock is down 3.3% in the year to date, while the S&P 500 has gained 9%.

-Barbara Kollmeyer

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 26, 2023 10:28 ET (14:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.